Hematopoietic Cell Transplantation for Breast Cancer — CPB 0507 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0507 governing hematopoietic cell transplantation for breast cancer, effective January 5, 2026. CPT codes 38205, 38206, 38230, and 38241—plus HCPCS S2150—remain non-covered for this indication, with a narrow exception for NCI- or FDA-sponsored clinical trials.

This update to the Aetna hematopoietic cell transplantation coverage policy doesn't open new doors for reimbursement. If your team bills transplant procedures for breast cancer patients covered under Aetna plans, the denial wall is still standing—and this policy revision makes the clinical rationale explicit. Know the exception criteria cold, because that's the only path to coverage.

Quick-Reference Table

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2026

Under CPB 0507 in the Aetna system, hematopoietic cell transplantation for breast cancer carries an experimental and investigational designation across all three transplant types. That means autologous, tandem, and allogeneic transplants all fall into the non-covered bucket as a default.

The one exception that matters for your billing team: Aetna will cover these procedures when they are performed in a clinical trial sponsored or authorized by the National Cancer Institute (NCI) or the U.S. Food and Drug Administration (FDA). That's the entire coverage pathway. There is no separate medical necessity criteria that unlocks coverage outside of a qualifying trial.

Note: CPB 0507 does not specify prior authorization requirements. The following recommendation is the blog author's guidance based on standard payer practices for high-cost experimental procedures. Given the experimental designation and the high cost of transplant procedures, treat prior auth as mandatory. Do not submit claims under CPT 38205, 38206, 38230, or 38241 for breast cancer without confirming coverage and trial eligibility with Aetna first.

The clinical rationale here is clear-cut. Four randomized controlled trials showed autologous hematopoietic cell transplantation was either equivalent to or worse than standard-dose chemotherapy for breast cancer. The Bezwoda study from South Africa—the one trial that showed a clinical benefit—has been called into question over data falsification concerns. Aetna's position reflects that evidence record, and it's unlikely to shift without new trial data.

Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications

All three transplant approaches are excluded for breast cancer under this coverage policy unless the clinical trial exception applies.

Autologous hematopoietic cell transplantation — non-covered. This is where the most billing exposure sits. Autologous transplants were the most studied approach and the one most often pursued outside trial settings. Aetna's denial position on this is firm.

Tandem hematopoietic cell transplantation — non-covered. Two sequential transplants don't change the coverage calculus. Tandem approaches carry the same experimental designation.

Allogeneic hematopoietic cell transplantation — non-covered for breast cancer indications per CPB 0507. CPT 38205 (allogeneic peripheral blood progenitor cell harvesting) and CPT 38230 (allogenic bone marrow harvesting) both fall under the non-covered group for breast cancer diagnoses.

One carve-out exists beyond the clinical trial exception. Aetna will cover any of these transplant types off-trial when state mandates or other legal requirements compel coverage. If you operate in a state with mandated coverage laws for experimental cancer treatments, check your state's specific requirements. That state mandate exception could be the difference between a claim denial and a paid claim. Loop in your compliance officer if you're unsure whether your state has applicable mandates.

Coverage Indications at a Glance

Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0507

Not Covered CPT Codes for Breast Cancer Indications

These four CPT codes are explicitly listed as not covered for the indications in CPB 0507. Coverage is available only under the clinical trial or state mandate exceptions described above.

Not Covered HCPCS Code for Breast Cancer Indications

Key ICD-10-CM Diagnosis Codes Under CPB 0507

These diagnosis codes represent the breast cancer indications to which CPB 0507 applies. Claims pairing these codes with the CPT or HCPCS codes above will trigger the experimental designation and denial—absent documented trial eligibility or a state mandate.

The full ICD-10 range across the D05.x subcategories runs 95 codes total in the Aetna policy document. If you bill for in situ breast lesions and transplant procedures together, every D05 subcode is mapped to this policy. Pull the complete list from the source policy at CPB 0507 before finalizing your charge capture rules.